Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
von Willebrand factor in factor VIII concentrates protects against neutralization by factor VIII antibodies of haemophilia A patients
Autore:
Kallas, A; Talpsep, T;
Indirizzi:
Univ Tartu, Dept Pharm, EE-51014 Tartu, Estonia Univ Tartu Tartu EstoniaEE-51014 u, Dept Pharm, EE-51014 Tartu, Estonia Univ Tartu, Inst Mol & Cell Biol, EE-51014 Tartu, Estonia Univ Tartu Tartu Estonia EE-51014 l & Cell Biol, EE-51014 Tartu, Estonia
Titolo Testata:
HAEMOPHILIA
fascicolo: 4, volume: 7, anno: 2001,
pagine: 375 - 380
SICI:
1351-8216(200107)7:4<375:VWFIFV>2.0.ZU;2-O
Fonte:
ISI
Lingua:
ENG
Soggetto:
HALF-LIFE; SPECIFICITY; INHIBITORS; BINDING;
Keywords:
factor VIII antibody; factor VIII; haemophilia A; von Willebrand factor;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
13
Recensione:
Indirizzi per estratti:
Indirizzo: Kallas, A Univ Tartu, Dept Pharm, Jakobi 2, EE-51014 Tartu, Estonia Univ Tartu Jakobi 2 Tartu Estonia EE-51014 51014 Tartu, Estonia
Citazione:
A. Kallas e T. Talpsep, "von Willebrand factor in factor VIII concentrates protects against neutralization by factor VIII antibodies of haemophilia A patients", HAEMOPHILIA, 7(4), 2001, pp. 375-380

Abstract

We investigated the neutralization activity of factor VIII (FVIII) antibodies of 12 haemophilia A patients, acquired during treatment with plasma-derived FVIII concentrates. All plasma samples, drawn in a clinically stable situation before any immunotolerance treatment, contained anti-A2 domain andanti-light-chain FVIII antibodies. In nine patients' plasmas, containing relatively high amounts of FVIII light-chain antibodies (53-96%), a higher neutralization activity was found against recombinant FVIII concentrate (Recombinate) than against plasma-derived von Willebrand factor (vWF)-containing concentrate (Haemoctin SDH). No difference in neutralization of the two concentrates was found in two patients' plasmas with almost equal content ofFVIII light- and heavy-chain antibodies, or one plasma with predominantly heavy-chain antibodies. These results suggest that haemophilia A patients with relatively high amounts of FVIII light-chain antibodies in plasma mightbenefit by infusion of FVIII concentrates containing vWF because vWF appears to have some protective effect on FVIII. This hypothesis should be tested by a clinical study.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 10/07/20 alle ore 08:37:12